PLK1 and small cell lung carcinoma: While some of these correlations were not significant after adjustment for multiple testing (8.68 × 10−5 ≤ pO ≤ 0.0006, pFDR ≥ 0.1657; data not shown), MYC probes cg08526705 and cg00163372 were associated with resistance to the PLK-1 inhibitor TAK-960 (statistically significant for cg08526705 in the body of MYC and TAK-960, ρ = 0.5432, pO= 2.45 × 10−5, pFDR = 0.0540; Table 3, Supplementary Tables 6 and 7) and to Aurora kinase inhibitors SCH-1473759 and GSK-461364, consistent with earlier studies of SCLC and with interaction of Aurora kinase A with c-Myc [8, 10, 58].